CVE-2026-21997 Overview
CVE-2026-21997 is an improper access control vulnerability affecting the Common Core component of Oracle Life Sciences Empirica Signal, a product within Oracle Life Science Applications. This easily exploitable flaw allows a low-privileged attacker with network access via HTTP to compromise the affected system, with the potential to significantly impact additional products beyond the vulnerable application itself.
Critical Impact
Successful exploitation enables unauthorized creation, deletion, or modification of critical data, as well as unauthorized read access to sensitive information. The scope change characteristic means attacks can propagate beyond the vulnerable component to affect other systems.
Affected Products
- Oracle Life Sciences Empirica Signal versions 9.2.1 through 9.2.3
- Common Core component within Oracle Life Science Applications
Discovery Timeline
- April 21, 2026 - CVE-2026-21997 published to NVD
- April 22, 2026 - Last updated in NVD database
Technical Details for CVE-2026-21997
Vulnerability Analysis
This vulnerability stems from improper access control (CWE-284) in the Common Core component of Oracle Life Sciences Empirica Signal. The flaw allows authenticated users with low-level privileges to perform actions beyond their authorized scope, affecting both confidentiality and integrity of the system.
The network-accessible nature of this vulnerability via HTTP means that any authenticated user on the network can potentially exploit it without requiring complex attack chains or user interaction. The scope change characteristic is particularly concerning, as it indicates that a successful attack against Oracle Life Sciences Empirica Signal can cascade to impact other products and systems that interact with or depend on the compromised application.
Root Cause
The vulnerability is rooted in improper access control mechanisms (CWE-284) within the Common Core component. This typically manifests as insufficient authorization checks that fail to properly validate whether authenticated users have appropriate permissions before allowing access to sensitive operations or data. The affected versions (9.2.1-9.2.3) contain authorization logic that does not adequately restrict low-privileged users from accessing or modifying resources that should require elevated permissions.
Attack Vector
The attack is conducted over the network via HTTP, requiring only low-privilege authentication to execute. An attacker would:
- Authenticate to the Oracle Life Sciences Empirica Signal application with any valid low-privileged account
- Craft HTTP requests targeting the Common Core component
- Bypass access control restrictions to access, modify, or delete critical data
- Potentially leverage the scope change to affect additional connected products or services
The low attack complexity combined with no required user interaction makes this vulnerability particularly attractive for exploitation. Detailed technical analysis is available in the Oracle Critical Patch Update April 2026.
Detection Methods for CVE-2026-21997
Indicators of Compromise
- Unexpected data modifications or deletions in Oracle Life Sciences Empirica Signal databases
- Anomalous HTTP requests from low-privileged user accounts targeting Common Core component endpoints
- Unauthorized access attempts to critical data resources not normally accessible to standard users
- Suspicious cross-product access patterns indicating scope expansion beyond Empirica Signal
Detection Strategies
- Implement monitoring for HTTP requests to the Common Core component, particularly from accounts that should not have elevated access
- Deploy web application firewall (WAF) rules to detect and block suspicious authorization bypass attempts
- Enable detailed audit logging for all data access, creation, modification, and deletion operations
- Configure alerts for unusual patterns of data access from low-privileged accounts
Monitoring Recommendations
- Review Oracle Life Sciences Empirica Signal access logs regularly for anomalous activity patterns
- Monitor for privilege escalation attempts and unauthorized cross-product access
- Implement real-time alerting for critical data modification events
- Establish baseline normal behavior for user accounts to identify deviations
How to Mitigate CVE-2026-21997
Immediate Actions Required
- Apply the security patch from the Oracle Critical Patch Update April 2026 immediately
- Audit user accounts and enforce principle of least privilege for all Empirica Signal users
- Implement network segmentation to limit exposure of the affected component
- Enable enhanced logging and monitoring for the Common Core component
Patch Information
Oracle has released security updates addressing this vulnerability as part of the April 2026 Critical Patch Update. Organizations should prioritize applying these patches to all affected Oracle Life Sciences Empirica Signal installations running versions 9.2.1, 9.2.2, or 9.2.3. Detailed patch information and installation instructions are available in the Oracle Critical Patch Update April 2026.
Workarounds
- Implement strict network access controls to limit which users and systems can reach the Empirica Signal HTTP interface
- Review and restrict user permissions to only the minimum required for their roles
- Deploy a web application firewall with custom rules to detect and block potential exploitation attempts
- Consider temporarily disabling non-essential features of the Common Core component until patches can be applied
# Example: Review and restrict user access in Oracle
# Audit current user permissions for Empirica Signal
SELECT username, granted_role FROM dba_role_privs
WHERE granted_role IN (SELECT role FROM dba_roles WHERE role LIKE '%EMPIRICA%');
# Implement network-level restrictions via firewall rules
# Limit HTTP access to Empirica Signal to authorized IP ranges only
iptables -A INPUT -p tcp --dport 80 -s 10.0.0.0/8 -j ACCEPT
iptables -A INPUT -p tcp --dport 443 -s 10.0.0.0/8 -j ACCEPT
iptables -A INPUT -p tcp --dport 80 -j DROP
iptables -A INPUT -p tcp --dport 443 -j DROP
Disclaimer: This content was generated using AI. While we strive for accuracy, please verify critical information with official sources.


